-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VqEV7JikqI/xw3IsqNdedrLFMUJk+Gvgzwv82RgQT8gDmrUfuLTcJQc3VqxkvFR2 Cr0kn14a3xXf1IHk7/I4aQ== 0001144204-09-017929.txt : 20090331 0001144204-09-017929.hdr.sgml : 20090331 20090331164852 ACCESSION NUMBER: 0001144204-09-017929 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090317 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20090331 DATE AS OF CHANGE: 20090331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Yongye Biotechnology International, Inc. CENTRAL INDEX KEY: 0001398551 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 208051010 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-143314 FILM NUMBER: 09719669 BUSINESS ADDRESS: STREET 1: 3195 UPPER LEVEL RD. #182 CITY: ROBSON STATE: A1 ZIP: VOG 1XO BUSINESS PHONE: 604-720-4393 MAIL ADDRESS: STREET 1: 3195 UPPER LEVEL RD. #182 CITY: ROBSON STATE: A1 ZIP: VOG 1XO FORMER COMPANY: FORMER CONFORMED NAME: Golden Tan, Inc DATE OF NAME CHANGE: 20070504 8-K 1 v144759_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (date of earliest event reported): March 17, 2009

YONGYE BIOTECHNOLOGY INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)

Nevada
 
333-143314
20-8051010
     
(State of Incorporation)
 (Commission File No.)
(IRS Employer
Identification No.)
 

6th Floor, Suite 608, Xue Yuan International Tower,
No. 1 Zhichun Road, Haidian District, Beijing, PRC

(Address Of Principal Executive Offices) (Zip Code)
 
+86 10 8231 8626
(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, is Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[  ]  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 5.02                      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On March 17, 2009, the Board of Directors of Yongye Biotechnology International, Inc. (the “Company”) by a board meeting approved and ratified the appointment, effective as of March 25, 2009, of Sam (Yue) Yu to serve as Chief Financial Officer of the Company.  Mr. Yu is employed under a three year employment contract  providing for an annual base salary of $145,000 and a discretionary bonus.  Before joining the Company, Mr. Yu provided capital market consulting services for Chinese companies listed on NASDAQ.  Prior to that,  Mr. Yu had served as Chief Operating Officer of Lionax International Investment Holding Ltd., a Chinese company listed on NYSE Euronext, from 2007 to 2008.  Mr. Yu also previously held positions of General Manager, Fire and Security Sector, Asia Pacific; General Manager, Suzhou Branch; Business Development Manager; and Manager of Financial Analysis; with Underwriters Laboratories Inc. in Asia and its Chicago headquarters from 2002 to 2007.  Mr. Yu was awarded a B.S. in Accounting at the University of International Business and Economics in China. He then earned an M.B.A. in General Management from the Stanford Graduate School of Business.
 
Mr. Yu has no family relationships with any of the executive officers or directors of the Company.  There have been no transactions in the past two years to which the Company or any of its subsidiaries was or is to be a party, in which Mr. Yu had, or will have, a direct or indirect material interest.
 
In addition, the Board ratified the acceptance on March 17, 2009 of the resignation of Larry Gilmore as Interim Principal Financial Officer of the Company, effective as of March 25, 2009.   Upon resignation, Mr. Gilmore continues to serve as VP Corporate Strategy of the Company.
 
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
YONGYE BIOTECHNOLOGY INTERNATIONAL, INC.
  
       
 
By:
/s/ Zishen Wu  
   
Name:  Zishen Wu
  
   
Title:    President and CEO
  
       
Dated: March 31, 2009
 
 
 
 
 
 
 
 
 
3
 
 -----END PRIVACY-ENHANCED MESSAGE-----